Longevity, Interpreted.
A scientist’s reading of the evidence
Most longevity claims travel further than their evidence. Each week I read the primary literature, the trial registries and the regulators, and report how far: what was shown, at what stage, and what it does not yet support.
Get this weekly, freeFree · Saturday and Sunday · one click to leave
- Every claim carries its stage of evidence, from a mouse study to a randomised human outcome trial.
- When new work changes nothing, the issue says so, and why. That is most weeks.
- Nothing to sell you. No clinic, no supplement line, no intervention I am paid to defend.
- Global signal, read with an India lens.
Also on suchee.org
Health by ageMost longevity news is early. These plain guides cover what is already proven, stage by stage, with Indian sources first.
The latest issue · 19–25 October 2026
Business
- Regeneron says trevogrumab preserved lean and muscle mass during GLP-1 weight loss
- Longevity clinic leaders called for standardised care as health systems open their own programmes
Healthspan
- Products sold as cat's claw contained undeclared kratom alkaloids and tianeptine
- Regeneron says trevogrumab preserved muscle mass during GLP-1 weight loss, and nobody reported strength
- A PhenoAge clock reading rose with tumour stage, and may be tracking cancer rather than aging
- THE THREAD THIS WEEK
Every issue
- 19–25 October 2026Business · Healthspan
- 12–18 October 2026Business · Healthspan
- 5–11 October 2026Business · Healthspan
- 28 September – 4 October 2026Business · Healthspan
- 21–27 September 2026Business · Healthspan
- 14–20 September 2026Business · Healthspan
- 7–13 September 2026Business · Healthspan
- 31 August – 6 September 2026Business · Healthspan
Edited by
Sucheendra Kumar Palaniappan
Scientist working at the intersection of computation, biology and medicine. Longevity, Interpreted. exists to understand the evidence, not sell an intervention.
All issues · Subscribe · Health by age · suchee.org · LinkedIn · Scholar
Mice are not humans · Biomarkers are not outcomes
· Funding is not validation